Exicure: Exicure is a clinical-stage biotechnology company developing immuno-oncology and gene regulatory therapeutics based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed, synthetic nucleic acid sequences, which are radially arranged in three dimensions. We believe that the design of our SNAs gives rise to distinct advantages over other nucleic acid therapeutics which may enable increased efficacy, improved safety, and less frequent dosing, in a variety of therapeutic indications. At Feb. 29, 2020 we had approx. $107.7 million of cash, cash equivalents, and short-term investments which we believe funds the company into 2022

Immuno-oncology: Exicure is completing the Phase 1b stage of its Phase 1b/2 clinical trial of AST-008 and is preparing to begin in Q2 2020 the Phase 2 stage of dose expansion for intratumoral AST-008 in combination with checkpoint inhibitors in patients with advanced or metastatic Merkel cell carcinoma or cutaneous squamous cell carcinoma.

Neurology: Exicure is developing XCUR-FXN, an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Preclinical research is ongoing and IND-enabling studies for XCUR-FXN are expected in late 2020.

Exicure entered into a collaboration with Allergan Pharmaceuticals International Limited in late 2019 and is now actively engaged in preclinical research and discovery in two clinical programs related to the treatment of hair loss disorders.
Based in...
US - East North Central
Public, USA
Market Cap
100MM - 500MM
8045 Lamon Ave.
Suite 410
Skokie, IL 60077
United States

Company Participants at Solebury Trout Corporate Access Calls - May 11&12

  • David Giljohann, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Exicure, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Tybourne Capital Management (HK) Ltd. 16.54 7,340,000 17.47 13F 2020-03-31
Abingworth LLP 15.72 6,977,000 16.61 13F 2020-03-31
AWM Investment Co., Inc. 9.11 4,042,200 9.62 13F 2020-03-31
Sphera Funds Management Ltd. 7.40 3,284,795 7.82 13F 2020-03-31
Ecor1 Capital LLC 6.40 2,841,301 6.76 13F 2020-03-31
The Vanguard Group, Inc. 6.18 2,743,779 6.53 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 6.11 2,709,380 6.45 13F 2020-03-31
Northwestern University 3.53 1,564,372 3.72 13F 2020-03-31
Granite Point Capital Management LP 2.88 1,278,052 3.04 13F 2020-03-31
Knoll Capital Management LP 2.88 1,277,777 3.04 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.